Stay alert to the latest and greatest on stem cells! Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on fun and fascinating findings within the world of stem cells.
BioInformant is honored to be a sponsor for the upcoming “Perinatal Stem Cell Society Conference” in Aspen, Colorado, over March 2-4, 2016. This 3-day event will feature the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. BioInformant’s sponsorship of the event is in collaboration with Save the Cord Foundation, as part of our partnership to promote cord blood banking awareness around the world.
The Perinatal Stem Cell Society was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many disorders. It will be hosting a scientific program with topics covering all aspects of the perinatal stem cell field. Attendees are actively advancing perinatal stem cell research, and focused on paths towards treatment. [Read more…]
Cellular Dynamics International Announces Launch of CIRM hPSC Repository and First 300 iPSC Lines
Cellular Dynamics International (CDI), a FUJIFILM company since March of 2015, announced news today that has reverberated throughout the stem cell community, suggesting hope and progress for the future of stem cell research.
As an indisputable leader in the the manufacture and production of iPS cell products, Cellular Dynamics was awarded a $16 million grant by the California Institute of Regenerative Medicine in March of 2013. In that landmark funding awarded, CIRM allocated $16 million for CDI to create 3 induced pluripotent stem cell (iPSC) lines from 3000 healthy and diseased donors. At the same time, CIRM awarded Coriell Institute approximately $10 million to structure and store the iPSC lines within a secure biobanking facility, of which CDI was to be a “primary subcontractor.” [Read more…]
Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, scientists have recognized the incredible potential of the cell type, including their utility in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more. Given the financial potential of the cell type, it is important to have strategies for accessing key individuals, events, and iPSC facilities.
In this post, we explore seven momentous partnerships that have been formed for purposes of strengthening company dominance within the induced pluripotent stem cell (iPS cell or iPSC) industry. As you’ll discover, a major theme among the “power players” within the iPSC marketplace is non-exclusive agreements with iPS Academia Japan.
These non-exclusive agreements allow companies access to an absolutely critical iPSC patent portfolio by granting access to the patented discoveries of Dr. Shinya Yamanaka, the scientist who invented induced pluripotent stem cells in 2006.